Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Conleth G Murphy

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Oncology|May 19, 2019
The Role of CDK4/6 Inhibitors in Breast CancerConleth G Murphy
Oncology (Williston Park, N.Y.)|May 20, 2010
HER2-positive breast cancer: beyond trastuzumabConleth G Murphy, Monica Fornier
Biologics : Targets & Therapy|August 27, 2009
HER2 breast cancer therapies: a reviewConleth G Murphy, Shanu Modi
Clinical Breast Cancer|July 15, 2009
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanesConleth G Murphy, Andrew D Seidman
The Oncologist|April 17, 2015
The Role of CDK4/6 Inhibition in Breast CancerConleth G Murphy, Maura N Dickler
Anti-Cancer Drugs|July 25, 2012
Recent advances in novel targeted therapies for HER2-positive breast cancerConleth G Murphy, Patrick G Morris
Endocrine-Related Cancer|July 14, 2016
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategiesConleth G Murphy, Maura N Dickler
Cancer Journal (Sudbury, Mass.)|February 19, 2010
BRCA gene structure and function in tumor suppression: a repair-centric perspectiveConleth G Murphy, Mary Ellen Moynahan
Anti-Cancer Drugs|June 9, 2015
CDK4/6 inhibitors in breast cancerTim Dukelow, Divya Kishan, Mustafa Khasraw, et al.
Plos One|July 19, 2016
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human CellsShuhei Ito, Conleth G Murphy, Ekaterina Doubrovina, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Oncology|May 19, 2019
The Role of CDK4/6 Inhibitors in Breast CancerConleth G Murphy
Oncology (Williston Park, N.Y.)|May 20, 2010
HER2-positive breast cancer: beyond trastuzumabConleth G Murphy, Monica Fornier
Biologics : Targets & Therapy|August 27, 2009
HER2 breast cancer therapies: a reviewConleth G Murphy, Shanu Modi
Clinical Breast Cancer|July 15, 2009
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanesConleth G Murphy, Andrew D Seidman
The Oncologist|April 17, 2015
The Role of CDK4/6 Inhibition in Breast CancerConleth G Murphy, Maura N Dickler
Anti-Cancer Drugs|July 25, 2012
Recent advances in novel targeted therapies for HER2-positive breast cancerConleth G Murphy, Patrick G Morris
Endocrine-Related Cancer|July 14, 2016
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategiesConleth G Murphy, Maura N Dickler
Cancer Journal (Sudbury, Mass.)|February 19, 2010
BRCA gene structure and function in tumor suppression: a repair-centric perspectiveConleth G Murphy, Mary Ellen Moynahan
Anti-Cancer Drugs|June 9, 2015
CDK4/6 inhibitors in breast cancerTim Dukelow, Divya Kishan, Mustafa Khasraw, et al.
Plos One|July 19, 2016
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human CellsShuhei Ito, Conleth G Murphy, Ekaterina Doubrovina, et al.
Pageof 2